UTHR logo

UTHR
United Therapeutics Corp

2,497
Mkt Cap
$22.91B
Volume
1.09M
52W High
$549.50
52W Low
$266.98
PE Ratio
18.74
UTHR Fundamentals
Price
$595.26
Prev Close
$522.83
Open
$604.09
50D MA
$495.92
Beta
0.46
Avg. Volume
376,933.71
EPS (Annual)
$27.86
P/B
3.22
Rev/Employee
$2.27M
$20,418.98
Loading...
Loading...
News
all
press releases
Biotech Stocks To Watch Today - March 30th
United Therapeutics, Danaher, and Vertex Pharmaceuticals are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop, and commercialize biological products and technologiessuch as drugs, vaccines, diagnos...
MarketBeat·52m ago
News Placeholder
More News
News Placeholder
Investors Buy High Volume of Call Options on United Therapeutics (NASDAQ:UTHR)
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) saw unusually large options trading activity on Monday. Traders acquired 16,791 call options on the stock. This represents an increase of 789% compared to the average volume of 1,888 call options...
MarketBeat·2h ago
News Placeholder
United Therapeutics (NASDAQ:UTHR) Shares Gap Up Following Analyst Upgrade
United Therapeutics (NASDAQ:UTHR) Shares Gap Up After Analyst Upgrade...
MarketBeat·3h ago
News Placeholder
Why Is United Therapeutics Stock Soaring Monday?
United Therapeutics (UTHR) stock surges 16% premarket after Tyvaso meets primary endpoint in pivotal IPF study. Get the full breakdown.read more...
Benzinga·4h ago
News Placeholder
United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, TD Cowen Analyst Says
TD Cowen lifted their target price on United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research report on Monday...
MarketBeat·4h ago
News Placeholder
Why Did UTHR Stock Surge Over 19% Pre-Market Today?
The company reported that its TETON-1 study to treat lung disease met its primary endpoint.
Stocktwits·6h ago
News Placeholder
United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-1 study evaluating the use of nebulized Tyvaso for the treatment of idiopathic pulmonary fibrosis (IPF) met its primary efficacy endpoint, demonstrating superiority over placebo for the...
Business Wire·7h ago
News Placeholder
Pallas Capital Advisors LLC Boosts Stake in United Therapeutics Corporation $UTHR
Pallas Capital Advisors LLC raised its position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 147.6% during the fourth quarter, according to the company in its most recent 13F...
MarketBeat·1d ago
News Placeholder
United Therapeutics Corporation $UTHR Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC grew its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 88.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,960 shares of the biotechnology co...
MarketBeat·1d ago
News Placeholder
United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the...
MarketBeat·1d ago
<
1
2
...
>

Latest UTHR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.